explore -WSS

explore

author：fashion 2025-10-01 20:14:05 - browse：71

CHICAGO — A next-generation CAR-T therapy was able to substantially shrink tumors in patients with liver cancer in early clinical data presented Monday at the American Society of Clinical Oncology annual meeting. The study, though preliminary and small with only 24 patients, represents a triad of firsts for one of the trial’s sponsors.

“It’s the first CAR therapy working in liver cancer. First validation of targeting GPC3 as a target. It’s the first validation of our armoring strategy. And it’s the first of many of our visions of CAR therapy in general,” Matt Hellmann, a medical oncologist and early development oncology lead at AstraZeneca, said in an interview.

This abstract, presented by cancer researcher Qi Zhang of Zhejiang University School of Medicine, is yet another significant showing by AstraZeneca at this ASCO. The company had two plenary presentations on its blockbuster lung cancer drug Tagrisso and immunotherapy drug Imfinzi — as well as new results on Enhertu, which AstraZeneca developed with Daiichi Sankyo.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Medical records are filled with copy
Next article： Synthetic human embryos? Researchers say term is overblown

explore

WSS

Lilly’s obesity pill cuts 15% of weight at highest dose in mid

Ukrainian soldiers say they owe lives to US

Hyaluronic acid injections don’t help knee osteoarthritis, study finds

GOP hopefuls to address prominent, controversial group questioning what's taught in schools

Biden slams SCOTUS affirmative action decision: 'Discrimination still exists in America'

Brazil's Jair Bolsonaro is barred from running for office until 2030

focus

explore

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

entertainment

Virginia high school admissions case could be legal follow

Will.i.am, Britney Spears release new single, 'Mind Your Business'

Moonlake's readout produced a cash windfall. Risks remain

Eating disorder hotline's move to chatbot carried cost for volunteers

Wildfire smoke exposes gaps in outdoor worker protections

As Taiwan prepares for anti

Medical records are filled with copy

A double vaccine crisis is endangering millions of children

The high cost of giving birth even with insurance

Contact tracing may help avoid another lockdown. Can it work in the U.S.?

entertainment

Medical experts exlpore how to eliminate bias in clinical algorithms

GOP inquiry over gain

Court strikes down limits on filming of police in Arizona

Medical experts exlpore how to eliminate bias in clinical algorithms

Death toll from an explosion and collapse of a Paris building in June climbs to 3

Court strikes down limits on filming of police in Arizona

hotspot

hotspot

explore

hotspot